title: Edema-induced changes in tumor cell surviving fraction and tumor control probability in 131Cs permanent prostate brachytherapy implant patients.
abstract: The study is designed to investigate the effect of edema on the delivered dose, tumor cell surviving fraction (SF), and tumor control probability (TCP) in the patients of prostate cancer who underwent (131)Cs permanent seed implantation. The dose reduction, the SF, and the TCP for edematous prostate implants were calculated for 31 patients who underwent real-time (131)Cs permanent seed implantation for edema half-lives (EHL), ranging from 4 days to 34 days and for edema magnitudes (M0) varying from 5% to 60% of the actual prostate volume. A dose reduction in (131)Cs implants varied from 1.1% (for EHL = 4 days and M(0) = 5%) to 32.3% (for EHL = 34 days and M(0) = 60%). These are higher than the dose reduction in 125I implants, which vary from 0.3% (for EHL = 4 days and M(0) = 5%) to 17.5% (for EHL = 34 days and M(0) = 60%). As EHL increased from 4 days to 34 days and edema magnitude increased from 5% to 60%, the natural logarithmic value of SF increased by 4.57 and the TCP decreased by 0.80. Edema induced increase in the SF and decrease in the TCP in (131)Cs seed implants, is significantly more pronounced in a combination of higher edema magnitude and larger edema half-lives than for less edema magnitude and lower edema half-lives, as compared for M(0) = 60% and EHL = 34, and M(0) = 5% and EHL = 4 days.
authors: Department of Radiation Oncology, University of Pittsburgh Cancer Institute, UPMC Cancer Centers, Pittsburgh, PA 15232, USA. drkehwar@gmail.com
authors: Than S
authors: TS
authors: Kehwar
authors: Heather A
authors: HA
authors: Jones
authors: M Saiful
authors: MS
authors: Huq
authors: Ryan P
authors: RP
authors: Smith
mesh_terms: D001918:Brachytherapy / Q000379:methods*; D002470:Cell Survival / Q000528:radiation effects; D002588:Cesium Radioisotopes / Q000627:therapeutic use*; D003198:Computer Simulation; D004487:Edema / Q000209:etiology / Q000503:physiopathology* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008954:Models, Biological; D015233:Models, Statistical; D011471:Prostatic Neoplasms / Q000150:complications / Q000503:physiopathology* / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002588:Cesium Radioisotopes; D019275:Radiopharmaceuticals